Article

Analysis of the adverse effects of used clinical Antisense Oligonucleotide drugs in DMD patients based on the FAERS database

2025-03-26

Abstract excerpt

not-yet-known not-yet-known not-yet-known unknown Introduction: Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder. With advancements in gene editing technology, antisense oligonucleotides (ASO) are utilized to treat DMD. These therapies partially restore dystrophin expression through exon skipping. However, the safety assessment of these drugs in clinical application remains lim...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 117b6aa5-0084-5412-83a0-2061b5205a7b
DOI: 10.22541/au.174298890.08753395/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Analysis of the adverse effects of used clinical Antisense Oligonucleotide drugs in DMD patients based on the FAERS databaseDOI 10.22541/au.174298890.08753395/v1Read

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBaseSemantic proximity Read

Adverse events induced by Burosumab treatment and prediction of drug target gene: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS) databaseSemantic proximity Read

Meeting Report: 2022 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Transfer Therapy’Semantic proximity Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS databaseSemantic proximity Read

Recent Trends in Antisense Therapies for Duchenne muscular dystrophySemantic proximity Read

Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?Semantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in FocusSemantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

Analysis and Mining of Baloxavir Marboxil Adverse Event Signals in Elderly Patients Based on the FAERS DatabaseSemantic proximity Read

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity Read